BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the safety, side effects and best dose of BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel and how well it works in treating patients with pancreatic adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that has come back after a period of improvement (recurrent). BMS-986340 is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel may be safe, tolerable, and/or effective in treating patients with metastatic or recurrent pancreatic adenocarcinoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat i starsze.
- •Potwierdzony rak trzustki.
- •Ogólny stan zdrowia pozwalający na aktywność (nie unieruchomiony w łóżku).
- •Choroba, którą można zmierzyć za pomocą badań obrazowych.
- •Pierwotnie zdiagnozowany rak trzustki z przerzutami lub nawrotowy.
- •Zdrowie serca w normie (badanie EKG bez istotnych nieprawidłowości).
- •Poziom hemoglobiny co najmniej 9.0 g/dL.
- •Poziom białych krwinek (WBC) co najmniej 2000/uL.
✗ Disqualifies
- •Pacjenci, którzy nie spełniają kryteriów ilościowych dla badań krwi i parametrów wątrobowych.
- •Pacjenci z nieprawidłowościami w EKG, które mogą wpływać na bezpieczeństwo badania.
- •Kobiety w ciąży lub karmiące piersią, lub osoby, które nie są w stanie zapewnić skutecznej antykoncepcji.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Mayo Clinic in Arizona
Scottsdale, United States
Mayo Clinic in Florida
Jacksonville, United States
Mayo Clinic in Rochester
Rochester, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.